| Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors AM Nash, MI Jarvis, S Aghlara-Fotovat, S Mukherjee, A Hernandez, ... Science Advances 8 (9), eabm1032, 2022 | 39 | 2022 |
| Bio-Engineering Approaches to Cancer Diagnosis and Treatment A Shahidian, M Ghassemi, J Mohammadi, M Hashemi Academic Press, 2020 | 10 | 2020 |
| Clinical and laboratory findings following transplantation of allogeneic adipose-derived mesenchymal stromal cells in knee osteoarthritis, a brief report B Sadri, A Tamimi, S Nouraein, A Bagheri Fard, J Mohammadi, ... Connective Tissue Research 63 (6), 663-674, 2022 | 8 | 2022 |
| Immune profiling of adeno-associated virus response identifies B cell-specific targets that enable vector re-administration in mice M Chen, B Kim, MI Jarvis, S Fleury, S Deng, S Nouraein, S Butler, S Lee, ... Gene therapy 30 (5), 429-442, 2023 | 4 | 2023 |
| Current and novel theranostic modalities for knee osteoarthritis B Sadri, S Nouraein, N Hossein-Khannazer, J Mohammadi, M Vosough | 4 | 2021 |
| Cancer vaccination: Various platforms and recent advances T Khodaei, B Sadri, S Nouraein, N Vahedi, J Mohammadi J. Immun. Biol 5, 151, 2020 | 3 | 2020 |
| Acoustically targeted noninvasive gene therapy in large brain volumes S Nouraein, S Lee, VA Saenz, HC Del Mundo, J Yiu, JO Szablowski Gene Therapy 31 (3), 85-94, 2024 | 1 | 2024 |
| Acoustically targeted noninvasive gene therapy in large brain regions S Nouraein, S Lee, VA Saenz, HC Del Mundo, J Yiu, JO Szablowski bioRxiv, 2023.01. 19.524626, 2023 | 1 | 2023 |
| Engineered serum markers for non-invasive monitoring of gene expression in the brain S Lee, S Nouraein, JJ Kwon, Z Huang, JA Wojick, B Xia, G Corder, ... Nature Biotechnology, 1-9, 2024 | | 2024 |
| Favorable preclinical efficacy and safety profile of AVB-001, a novel IL-2 cell-based immunotherapy that eradicates ovarian cancer in mouse tumor models and supports first-in … A Jazaeri, G Carmona, A Nash, R Newman, J Schladenhauffen, M Jarvis, ... Gynecologic Oncology 176, S170-S171, 2023 | | 2023 |
| Engineering Regionally-Activated Drugs for Neuroscience Z Huang, A Mitrofan, S Nouraein, C Horak, JP Seo, M Harb, R Jin, ... bioRxiv, 2023.10. 12.562069, 2023 | | 2023 |
| 1094 Favorable preclinical efficacy and safety profile of AVB-001 a novel IL-2 cell-based immunotherapy that eradicates ovarian cancer in mouse tumor models and supports first … G Carmona, A Nash, R Newman, J Schladenhauffen, M Jarvis, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| Tumor Adjacent IL2 Cytokine Factories Eradicates Ovarian Cancer in Mice Through Cytotoxic T-cell Activation with Safe and Predictable Dosing in Non-human Primates G Carmona, A Nash, M Jarvis, R Newman, J Schladenhauffen, ... The Journal of Immunology 208 (1_Supplement), 122.17-122.17, 2022 | | 2022 |
| Targeted immunosuppression enhances repeated gene delivery M Chen, B Kim, M Jarvis, S Fleury, S Deng, S Nouraein, S Butler, ... | | 2022 |
| 212 Tumor adjacent cytokine factories for eradication of ovarian cancer tumor burden in mice through cytotoxic T-cell activation with safe and predictable dosing in non-human … A Nash, M Jarvis, S Aghlara-Fotovat, S Mukherjee, A Hernandez, A Hecht, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | | 2021 |
| SECHENOV MEDICAL JOURNAL B SADRI, SH NOURAEIN, N HOSSEIN-KHANNAZER, J MOHAMMADI, ... SECHENOV MEDICAL JOURNAL Учредители: Первый Московский государственный …, 2021 | | 2021 |
| Antibody-Based Targeted Therapy: A Novel Cancer Treatment B Sadri, S Nouraein, T Khodaei, N Vahedi, J Mohammadi | | 2020 |
Javad MohammadiAssociate Professor at University of TehranVerified email at ut.ac.ir
